European journal of clinical investigation
-
Eur. J. Clin. Invest. · Jul 2023
A score for predicting invasive pulmonary aspergillosis in immunocompetent critically ill patients.
Delayed treatment leads to increased mortality in critically ill patients with invasive pulmonary aspergillosis (IPA). We aimed to develop and validate a prediction score based on novel biomarkers and clinical risk factors to identify IPA in immunocompetent patients in the intensive care unit (ICU). ⋯ A score based on six clinical and novel immunological biomarkers showed promising predictive value for antifungal treatment in immunocompetent ICU patients.
-
Eur. J. Clin. Invest. · Jul 2023
Review Meta AnalysisEvaluation of Heart Failure Admission as a Surrogate for Mortality in Randomized Clinical Trials: A Meta-Analysis.
Heart failure (HF) admission is used as a study endpoint in clinical trials. However, it remains unclear whether it can be a valid surrogate endpoint for mortality. ⋯ Our findings indicate that HF admission may not always be a valid surrogate for mortality in patients with HF. Rather, the surrogacy of HF admission may be dependent on clinical background and interventions.
-
Eur. J. Clin. Invest. · Jul 2023
Review Meta AnalysisMultifaceted Role of Galectin-4 In Cancer: A Systematic Review.
Galectins are β-galactoside-binding proteins. Galectin-4 has shown an effect on cancer progression/metastasis, especially in cancers of the digestive system. This can be attributed to altered glycosylation pattern of cell membrane molecules, which is a characteristic attribute of oncogenesis. The aim of this paper is to systematically review galectin-4 in different cancers and its role in disease progression. ⋯ A differential expression of galectin-4 was observed in different cancer stages/ and types. Furthermore, galectin-4 was found to modulate disease progression. A meta-analysis and comprehensive mechanistic studies, pertaining to different aspects of galectin-4 biology, could give statistically driven correlations, elucidating multifaceted role of galectin-4 in cancer.
-
Eur. J. Clin. Invest. · Jul 2023
Multicenter StudyAge-differences of patients treated with wearable cardioverter defibrillator: data from a multicenter Registry.
Wearable cardioverter defibrillators (WCD) are used as a 'bridging' technology in patients, who are temporarily at high risk for sudden cardiac death (SCD). Several factors should be taken into consideration, for example patient selection, compliance and optimal drug treatment, when WCD is prescribed. We aimed to present real-world data from seven centres from Germany and Switzerland according to age differences regarding the outcome, prognosis, WCD data and compliance. ⋯ Although the compliance rate in different age groups is high, the average wear hours tended to be lower in young patients compared to older patients. The clinical events were similar in younger patients compared to older patients.